Aug 03, 2021 / 04:20AM GMT
Nadine Blayney - ausbiztv - Media
Hi there, and welcome back to the NWR Communications Investor Virtual Conference this year, of course. It's the eighth in the series. And we return to you with another great company, SUDA Pharmaceuticals. It's a biotech company that's focused on developing therapies to treat human disease.
The two focus areas for SUDA are oncology and conditions that impact the central nervous system. So it's developing its invariant natural killer T, iNKT, cell therapy platform from Imperial College London, to treat blood cancers in particular, as well as low-risk oral sprays to reformulate existing pharmaceuticals.
(Conference Instructions) Presenting today for SUDA Pharmaceuticals is Dr. Michael Baker. He is CEO and MD. Michael?
Michael Baker - SUDA Pharmaceuticals Ltd. - CEO & MD
Thanks very much, Nadine. Thanks for having me. And thanks to NWR for putting on the event. And thanks to everybody else for dialing in and taking the time. We really appreciate it. And I'm looking forward to taking you through some of what
Suda Pharmaceuticals Ltd at NWR Communications Investor Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)